Brief: Mauna Kea Supports Research Use Of Cellvizio On COVID-19 Patients
March 17 (Reuters) - MAUNA KEA TECHNOLOGIES SAS MKEA.PA :
* MAUNA KEA TECHNOLOGIES SUPPORTS CLINICAL RESEARCH
EVALUATING USE
OF CELLVIZIO ON COVID-19 PATIENTS WITH RESPIRATORY INSUFFICIENCY
* CO IS OFFERING IN-KIND FUNDING TO RESEARCHERS EVALUATING
WHAT
ROLE CELLVIZIO MAY PLAY IN CARE MANAGEMENT OF COVID-19 PATIENTS
Source text for Eikon: ID:nBw2tMw7Ga
Further company coverage: MKEA.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Mauna Kea Technologies SA
See all newsBrief: Mauna Kea Technologies Confirms Trajectory Toward Profitability By Year-End 2027
Brief: Mauna Kea Technologies Announces Results Of Its Combined General Meeting
French and Benelux stocks-Factors to watch 21 Nov
Brief: Mauna Kea Technologies Receives NMPA Regulatory Approval In China For Its Next-Generation Cellvizio Platform
Europe Research Roundup: Craneware, Croda, Genus